Druker, Brian J <br/><br/>
Taking aim at Ewing's sarcoma: is KIT a target and will imatinib work?  [electronic resource] 

 -  Journal of the National Cancer Institute  Nov 2002 
 - 1660-1 p.  digital 
<br/><br/> Publication Type: Comment; Editorial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>0027-8874 
<br/><br/><label>Standard No.: </label>10.1093/jnci/94.22.1660  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents--pharmacology<br/>Benzamides<br/>Bone Neoplasms--drug therapy<br/>Clinical Trials, Phase I as Topic<br/>Dose-Response Relationship, Drug<br/>Enzyme Inhibitors--pharmacology<br/>Humans<br/>Imatinib Mesylate<br/>Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy<br/>Piperazines--pharmacology<br/>Protein-Tyrosine Kinases--antagonists & inhibitors<br/>Proto-Oncogene Proteins c-kit--drug effects<br/>Pyrimidines--pharmacology<br/>Sarcoma, Ewing--drug therapy<br/>Treatment Outcome<br/>Tumor Cells, Cultured